Liquid biopsy involves the analysis of a blood sample for genetic markers. Credit: PublicDomainPictures from Pixabay.

Clinical cancer genomics company Inivata has raised $52.6m in a series B funding round to support the commercialisation of its InVisionFirst lung liquid biopsy test in the US.

The financing round was joined by Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital, Johnson & Johnson Innovation, JJDC and RT Ventures.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

InVisionFirst-Lung is based on Inivata’s InVision platform, which is designed to explore genomic information using a blood test. It detects cancer mutations and delivers molecular insights that can be used by clinicians to make more informed decisions for the treatment of patients with non-small-cell lung cancer (NSCLC).

InVisionFirst-Lung secured coverage for US Medicare patients with advanced NSCLC, allowing its use in routine clinical care.

“This series B financing allows us to commercialise our lead product in patients with advanced lung cancer.”

Apart from advancing release, the funds will be used to support the development of new InVision platform indications.

Inivata CEO Clive Morris said: “This series B financing allows us to commercialise our lead product in patients with advanced lung cancer, following our positive reimbursement decision.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We also have an exciting portfolio of future products that will be advanced in parallel to maximise the benefits of our industry-leading InVision Liquid Biopsy platform to patients.”

Liquid biopsy involves the extraction of a blood sample from patients. The sample is then analysed for genetic markers associated with the presence of circulating tumour DNA (ctDNA).

Shed by tumours, ctDNA is known to comprise genetic information that could enable monitoring of treatment progress and identification of developing resistance.

Inivata partners with industry and academic researchers for creating new clinical applications for liquid biopsy and ctDNA analysis.